论文部分内容阅读
目的:观察参附注射液对重型颅脑损伤亚低温治疗患者神经的保护作用。方法:将33例重型颅脑损伤亚低温治疗患者随机分为2组,对照组16例予亚低温及常规治疗,治疗组17例在对照组的基础上加用参附注射液静脉滴注,观察2组治疗后颅内压(ICP)、脑脊液(CSF)生化指标变化及统计格拉斯哥昏迷评分(GCS)、格拉斯哥预后评分(GOS)。结果:治疗第5、6、7天,治疗组ICP改善优于对照组(P<0.05)。治疗第3、5、7天,治疗组S-100B蛋白降低较对照组更显著(P<0.05)。治疗后第5、7天,治疗组CK值降低较对照组更显著(P<0.05)。治疗第14、28天,治疗组GSC评分高于对照组。随访3月,治疗组GOS评分高于对照组(P<0.05)。结论:参附注射液对重型颅脑损伤接受亚低温治疗患者具有急性期神经保护,并改善患者预后。
Objective: To observe the neuroprotective effects of Shenfu injection on mild hypothermia patients with severe craniocerebral injury. Methods: Thirty-three patients with severe craniocerebral injury treated with mild hypothermia were randomly divided into two groups. Sixteen patients in the control group were treated with mild hypothermia and routine therapy. Seventeen patients in the treatment group received intravenous infusion of Shenfu injection on the basis of the control group. The intracranial pressure (ICP), changes of CSF biochemical indexes and Glasgow Coma Scale (GCS) and Glasgow Outcome Scale (GOS) were observed in two groups after treatment. Results: On the 5th, 6th and 7th day of treatment, the improvement of ICP in the treatment group was better than that in the control group (P <0.05). On the 3rd, 5th and 7th day after treatment, the S-100B protein in the treatment group was significantly lower than that in the control group (P <0.05). On the 5th and 7th day after treatment, the CK value in the treatment group was significantly lower than that in the control group (P <0.05). On the 14th and 28th days of treatment, the GSC score of the treatment group was higher than that of the control group. Followed up in March, the GOS score of the treatment group was higher than that of the control group (P <0.05). Conclusion: Shenfu injection has acute phase neuroprotection in patients with severe traumatic brain injury treated with mild hypothermia, and improves prognosis.